CA2569196A1 - Genotype fcgr3 et methodes d'evaluation de reponses therapeutiques a des anti-corps non depletifs - Google Patents
Genotype fcgr3 et methodes d'evaluation de reponses therapeutiques a des anti-corps non depletifs Download PDFInfo
- Publication number
- CA2569196A1 CA2569196A1 CA002569196A CA2569196A CA2569196A1 CA 2569196 A1 CA2569196 A1 CA 2569196A1 CA 002569196 A CA002569196 A CA 002569196A CA 2569196 A CA2569196 A CA 2569196A CA 2569196 A1 CA2569196 A1 CA 2569196A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- amino acid
- receptor
- subject
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57541104P | 2004-06-01 | 2004-06-01 | |
| US60/575,411 | 2004-06-01 | ||
| PCT/IB2005/002310 WO2005118854A1 (fr) | 2004-06-01 | 2005-05-31 | Genotype fcgr3 et methodes d'evaluation de reponses therapeutiques a des anti-corps non depletifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2569196A1 true CA2569196A1 (fr) | 2005-12-15 |
Family
ID=35159825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002569196A Abandoned CA2569196A1 (fr) | 2004-06-01 | 2005-05-31 | Genotype fcgr3 et methodes d'evaluation de reponses therapeutiques a des anti-corps non depletifs |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1751310A1 (fr) |
| JP (1) | JP2008500832A (fr) |
| CA (1) | CA2569196A1 (fr) |
| WO (1) | WO2005118854A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008205543A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| WO2009048027A1 (fr) | 2007-10-09 | 2009-04-16 | Arkray, Inc. | Sonde pour détecter un polymorphisme dans un gène impliqué en immunité et son utilisation |
| EP2350318A4 (fr) * | 2008-10-22 | 2012-04-18 | Univ Michigan | Procédés, compositions et kits pour diagnostiquer, surveiller et traiter une maladie |
| JP2013528599A (ja) * | 2010-05-14 | 2013-07-11 | アムジェン インコーポレイテッド | 増強デスレセプター・アゴニスト |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| WO2019222293A1 (fr) * | 2018-05-14 | 2019-11-21 | Indapta Therapeutics, Inc. | Sous-ensembles de cellules tueuses naturelles humaines présentant des réponses immunitaires dirigées contre des anticorps améliorées |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919194D0 (en) * | 1999-08-14 | 1999-10-20 | Univ Leeds | Genetic marker for rheumatoid arthritis |
| DK1436427T3 (da) * | 2001-10-19 | 2008-12-08 | Chru Tours | Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons |
| DK1553975T3 (da) * | 2002-09-27 | 2012-05-07 | Xencor Inc | Optimerede Fc-varianter og fremgangsmåder til generering heraf. |
-
2005
- 2005-05-31 EP EP05768688A patent/EP1751310A1/fr not_active Withdrawn
- 2005-05-31 CA CA002569196A patent/CA2569196A1/fr not_active Abandoned
- 2005-05-31 JP JP2007514215A patent/JP2008500832A/ja active Pending
- 2005-05-31 WO PCT/IB2005/002310 patent/WO2005118854A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005118854A1 (fr) | 2005-12-15 |
| WO2005118854B1 (fr) | 2006-04-06 |
| JP2008500832A (ja) | 2008-01-17 |
| EP1751310A1 (fr) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6905163B2 (ja) | サイトカイン放出症候群を予測するバイオマーカー | |
| Kroner et al. | A PD‐1 polymorphism is associated with disease progression in multiple sclerosis | |
| JP6815992B2 (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| US9683049B2 (en) | Modulation of TIM receptor activity in combination with cytoreductive therapy | |
| JP5130044B2 (ja) | ４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物 | |
| KR20220105664A (ko) | Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도 | |
| JP6941561B2 (ja) | 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン | |
| US20200369773A1 (en) | Cellular based therapies targeting disease-associated molecular mediators of fibrotic, inflammatory and autoimmune conditions | |
| US20070231813A1 (en) | Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies | |
| JP2022084710A (ja) | Ｃａｒ－ｔ細胞の投薬を決定するための方法 | |
| JP2021508317A (ja) | 遺伝子操作された細胞の投与および調節のための方法 | |
| CA2964363A1 (fr) | Compositions et methodes d'identification, d'evaluation, de prevention et de traitement du cancer au moyen de modulateurs et de biomarqueurs nfs39 | |
| JP2022513685A (ja) | 養子細胞療法を用いた処置のための方法 | |
| KR20220147109A (ko) | 키메라 항원 수용체 발현 세포의 제조 방법 | |
| CA2569196A1 (fr) | Genotype fcgr3 et methodes d'evaluation de reponses therapeutiques a des anti-corps non depletifs | |
| Fujii et al. | A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab | |
| KR20230052291A (ko) | Ceacam 양성 암을 치료하기 위한 조성물 및 방법 | |
| Hussain et al. | Impact of human FcγR gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format | |
| US20220112557A1 (en) | System and methods for monitoring adoptive cell therapy clonality and persistence | |
| KR20230051677A (ko) | 메소텔린 양성 암을 치료하기 위한 조성물 및 방법 | |
| WO2021092220A1 (fr) | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle | |
| Hullsiek et al. | Examination of IgG Fc receptor CD16A and CD64 expression by canine leukocytes and their ADCC activity in engineered NK cells | |
| KR20230052289A (ko) | Egfr 양성 암을 치료하기 위한 조성물 및 방법 | |
| KR20230029611A (ko) | T 세포를 선택적으로 조절하기 위한 이중특이적 분자 | |
| CA3201423A1 (fr) | Anticorps anti-cd25 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130531 |